STENT THROMBOSIS: INSIGHTS ON OUTCOMES, PREDICTORS AND IMPACT OF DUAL ANTIPLATELET THERAPY INTERRUPTION FROM THE SPIRIT II, SPIRIT III, SPIRIT IV AND COMPARE TRIALS  by Kedhi, Elvin et al.
ACC-i2 with TCT
E321
JACC March 27, 2012
Volume 59, Issue 13
STENT THROMBOSIS: INSIGHTS ON OUTCOMES, PREDICTORS AND IMPACT OF DUAL ANTIPLATELET 
THERAPY INTERRUPTION FROM THE SPIRIT II, SPIRIT III, SPIRIT IV AND COMPARE TRIALS 
i2 Oral Contributions
McCormick Place South, S101a
Sunday, March 25, 2012, 11:15 a.m.-11:25 a.m.
Session Title: Drug-eluting Stents
Abstract Category: 16. PCI - DES (clinical/outcomes)
Presentation Number: 2506-9
Authors: Elvin Kedhi, Gregg Stone, Dean Kereiakes, Patrick Serruys, Helen Parise, Martin Fahy, Charles Simonton, Krishnan Sudhir, Poornima Sood, 
Pieter Smits, Maasstad Hospital, Rotterdam, The Netherlands
Background : Recent studies have suggested that everolimus-eluting stent (EES) may reduce ST compared to paclitaxel-eluting stent (PES), but 
no individual trial has been adequately powered to give insights on incidence and predictors of stent thrombosis, as well as the impact of dual 
antiplatelet therapy (DAPT) discontinuation during the first 2 years.
Methods: Pooled patient-level data from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials (n=6,789 patients) were analyzed. Two-year ST rates 
were calculated using time-to-event methods and compared with the log-rank test. ST rates were also determined after DAPT discontinuation.
Results: EES compared to PES significantly reduced the 2-year rates of ST (0,7 % versus 2,3 % , p=0,0001), including the interval rates of ST up to 
30 days (0,2 % versus 1,0 %, p<0,0001), between 31 days and 1 year (0,2 % versus 0,6 %, p=0,02), and after 1 year (0,3 % versus 0,8 %, p=0,001). 
EES also reduced the 2-year composite rate of cardiac death or MI (4,0 % versus 6,6 %, p=0,0001). Increased rates of ST after DAPT discontinuation 
beyond 6 months were observed in the PES cohort, but not in the EES cohort.
Conclusions: In this large pooled analysis from four randomised trials, treatment with EES compared to PES significantly reduced the rates of ST 
through 2 years of follow-up, with a concomitant reduction in cardiac death or MI. DAPT discontinuation beyond 6 months may be safe with EES.
 
